Ionis Pharmaceuticals, Inc.

Good morning, and welcome to the IONIS Pharmaceuticals Third Quarter 2022 Financial Results Conference Call. As a reminder, this call is being recorded, and at this time, I would like to turn the conference over to Ms. Julie Tepper, Investor Relations, to lead off the call. Please go ahead, ma'am.

Thank you, Chuck. Before we begin, I encourage everyone to go to the Investors section of the IONIS website to view the press release and related financial tables we will be discussing today. including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We have also posted slides on our website that accompany today's call. With me this morning are Brett Monia, Chief Executive Officer, Richard Geary, Executive Vice President of Development, and Beth Haugen, Chief Financial Officer. And joining us for the Q&A portion of the call are Eric Swayze, Executive Vice President of Research, Eugene Schneider, Chief Clinical Development Officer, and Oneza Katare, Chief Global Product Strategy and Operations Officer. I would like to draw your attention to slide three, which contains our forward-looking statement. During this call, we will be making forward-looking language statements that are based on our current expectations and beliefs These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail. With that, I'll turn the call over to Brett.

Thanks, Julie. Good morning, everybody, and thanks for joining us on today's call. This year has been catalyst rich and strategically important for IONIS, enabling us to conclude 2022 in a position setting us up for substantial growth. We're looking forward to potentially adding two new commercial products from our rich Bay Street pipeline to our portfolio next year. These are, of course, Eplon-Tersen for ATTR polyneuropathy and Tofersen for SAD-1 ALS. In addition, we've made excellent progress advancing our late and mid-stage pipeline. With eight positive key data readouts so far this year, Our rich phase three pipeline is poised to expand with two new phase three starts expected in the first half of next year. And based on all our pipeline progress, we're well positioned to continue delivering a steady cadence of phase three data readouts in 2023, 2024, 2025, and beyond. This year, we have also advanced our commitment to deliver transformative medicines to the market with our go-to-market commercial preparations for our near-term product opportunities at Blantersen, Olazarsen, and Donna Dolorsen. We have also made great progress expanding and diversifying our technology with the recent advancement of three new programs into IND-enabling development activities. These programs involve our first medicines incorporating Leica technology for enhanced delivery to muscle, and our mesophosphoramidate, or MSPA, backbone chemistry designed to improve both efficacy and durability. These advancements further enhance and expand our drug discovery capabilities for both our new programs and our follow-on programs. We've also taken additional steps to support our future growth. We recently began work on a new state-of-the-art manufacturing facility. facility will ensure we have the capacity we need to continue to successfully deliver our medicines to patients and continue to expand into new chemistries. We also recently capitalized on the record demand for life science real estate assets by monetizing several of our facilities through a sale leaseback transaction. This transaction further strengthens our balance sheet to support our plans for accelerated growth. With that, I'll turn the call over to Richard to discuss our recent key data readouts, pipeline updates, and preview our upcoming catalysts. Then Beth will review our third quarter financial results, the financial impacts of our recent real estate transactions, as well as review our full year financial guidance. And after Beth, I'll wrap up our prepared remarks before taking your questions. So now over to Richard.